Petros PharmaceuticalsPTPI +0.20% 9-Day RSI is 28.89 as of Jul. 02, 2026. Among 1,048 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 93.51% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Petros Pharmaceuticals 9-Day RSI Related Terms
PTPI vs STEK, KOAN, GCAN: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a 9-Day RSI of 28.89 as of Jul. 02, 2026. According to the industry distribution chart, Petros Pharmaceuticals ranks #68 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 6.5%.
Is Petros Pharmaceuticals' 9-Day RSI too high?
Petros Pharmaceuticals' current 9-Day RSI is 28.89. The Drug Manufacturers industry median 9-Day RSI is 49.80. Petros Pharmaceuticals' value of 28.89 is 42% below this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #68 out of 1048 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' 9-Day RSI compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #68 out of 1048 companies for 9-Day RSI. This places Petros Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 49.80. Petros Pharmaceuticals' value of 28.89 is 42% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 49.80, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current 9-Day RSI of 28.89 is 42% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 49.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current 9-Day RSI is 28.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current 9-Day RSI of 28.89. The current 9-Day RSI is 28.89 and 42% below the Drug Manufacturers industry median of 49.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current 9-Day RSI is 28.89 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your